BUILT BY
SURVIVORS
& SCIENTISTS

OUR FOUNDERS

  • Michele Young

    Attorney and Stage 4 breast cancer survivor who organized the effort to pass legislation, in Ohio, for more comprehensive screening guidelines for early detection.

  • Kristen Dahlgren

    Award winning News correspondent and medical reporter for NBC News, Today Show, NBC Nightly News and MSNBC, for more than 2 decades. Breast Cancer Survivor.

Kristen and Michele, both breast cancer survivors, met when Kristen interviewed Michele for the NBC’s Today Show about Michele’s journey to survive stage 4 breast cancer and her quest to save other women from the devastating effects of the disease.

Michele had been diagnosed with de novo breast cancer in 2018 and was told to go through her bucket list. In that moment, she decided to save her life and all others. She researched, traveled to and met with the giants in the field and saw first-hand a revolution taking place that could end breast cancer.

Kristen was inspired by Michele, the doctors and the science. When she decided she was going to leave her career as an award-winning correspondent on NBC, she chose to act on this inspiration and form the Pink Eraser Project with Michele.

Kristen has seen from her career in journalism how even one person can change the world. She, too, realized we are at a unique moment in time when the right collaboration and funding could mean breast cancer vaccines within a decade. She could not let this opportunity pass without doing everything she could to build a future where no one must go through what she went through.

Together, they are leading this historic effort to end breast cancer as we know it.

THE SCIENTISTS

  • Dr. Nora Disis

    UW/CVI Director
    American Cancer Society Clinical Research Professor. Editor-in-Chief for JAMA Oncology
    Pioneering investigator and expert in breast and ovarian cancer immunology.

  • Dr. Larry Norton

    Medical Director, Evelyn H. Lauder Breast Center at Memorial Sloan Kettering Renowned as a leader in the development of drug treatments for breast cancer. Founding Scientific Director, BCRF.

  • Dr. Beth Mittendorf

    Brigham and Women's Hospital Vice Chair for Research, Co-Leader, Breast Program, Dana-Farber/Harvard Cancer Center. Director, Breast Immuno-Oncology program. Co-Leader, Parker Institute for Cancer Immunotherapy, Dana-Farber Cancer Institute

  • Dr. Powel Brown

    Molecular biologist and breast medical oncologist, MD Anderson Cancer Center

  • Dr. G. Thomas Budd

    Cleveland Clinic. Recently presented positive data from Phase I Trial of alpha-lactalbumin vaccine in high-risk operable triple negative breast cancer (TNBC) and patients at high genetic risk for TNBC

  • Dr. Shipra Gandhi

    Medical oncologist, breast cancer expert and Assistant Professor of Oncology
    Roswell Park Comprehensive Cancer Center (Buffalo, NY)

THE ADVISORY TEAM

  • Saranne Rothberg

    Stage IV cancer survivor. Founder, Comedy Cures Foundation Host, of the #1 ranked cancer survivor podcast, “Beating Cancer Daily.”

  • Sarah Audet

    Principal, Hedgehog & Fox Collaborative

  • John Cobey

    Legal Advisor

  • Kiran Dhillon, PhD

    Executive Director, Cancer Vaccine Institute University of Washington

  • Judy Lewent

    Former EVP & CFO, Merck & Co.

  • Andrew W. Lo

    Professor of Finance, and the Director of the Laboratory for Financial Engineering at the MIT Sloan School of Management

  • Cheryl Stamm

    Nonprofit Mentor. Advisor at Aviatra Accelerators

  • Dr. Elizabeth Levick, MD

    Radiation Oncologist

GET
INVOLVED